WO2019035057A2 - Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci - Google Patents

Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci Download PDF

Info

Publication number
WO2019035057A2
WO2019035057A2 PCT/IB2018/056200 IB2018056200W WO2019035057A2 WO 2019035057 A2 WO2019035057 A2 WO 2019035057A2 IB 2018056200 W IB2018056200 W IB 2018056200W WO 2019035057 A2 WO2019035057 A2 WO 2019035057A2
Authority
WO
WIPO (PCT)
Prior art keywords
exosome
peptide
target
thr
leu
Prior art date
Application number
PCT/IB2018/056200
Other languages
English (en)
Other versions
WO2019035057A3 (fr
Inventor
Chulhee Choi
Nambin YIM
Hojun CHOI
Kyungsun CHOI
Seung-Wook RYU
Original Assignee
Cellex Life Sciences, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2019035057(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellex Life Sciences, Incorporated filed Critical Cellex Life Sciences, Incorporated
Priority to CN201880067512.6A priority Critical patent/CN111629761B/zh
Priority to JP2020530742A priority patent/JP7224352B2/ja
Priority to CA3073162A priority patent/CA3073162C/fr
Priority to AU2018316803A priority patent/AU2018316803B2/en
Priority to US16/639,740 priority patent/US20200206360A1/en
Priority to EP18846900.1A priority patent/EP3668552A4/fr
Publication of WO2019035057A2 publication Critical patent/WO2019035057A2/fr
Publication of WO2019035057A3 publication Critical patent/WO2019035057A3/fr
Priority to IL272684A priority patent/IL272684A/en
Priority to AU2021250906A priority patent/AU2021250906B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Definitions

  • the present invention relates to a method for preparing an exosome that delivers a substance in a target specific manner and an exosome prepared by the method.
  • the human body is composed of about 200 kinds of 100 trillion cells, in which the physiological activity is regulated by the action of various proteins to maintain life.
  • Cells are surrounded by membranes in bilayer structure composed of phospholipids, which block the entry of foreign substances into cells.
  • Most of the protein drugs which have developed so far cannot pass through the cell membrane to enter the cell and can act on the outside of the cell or act on a receptor on the cell membrane to deliver the signal into the cell in order to show physiological effect.
  • Cytosol has lots of proteins which interact with each other to regulate physiological activity. So, if only a protein drug can be delivered inside the cell, that is, inside the cytosol, the cell activity would be controlled more effectively.
  • PTD protein transduction domains
  • a fusion protein prepared by combining the PTDs and a target protein is produced as a recombinant protein and at this time a separation process is required.
  • this process is problematic in that the protein refolding is not performed properly, the activity is decreased, the protein is nonspecifically transferred, the risk of causing an immune reaction in vivo is large, the cost is high, and the yield is low.
  • a target protein combined with various nanoparticles such as Gold NP (nano particle), Liposome NP, Magnetic NP, and Polymeric NP can enter the cytoplasm through the cell membrane by endocytosis.
  • nanoparticles such as Gold NP (nano particle), Liposome NP, Magnetic NP, and Polymeric NP
  • nanoparticles such as Gold NP (nano particle), Liposome NP, Magnetic NP, and Polymeric NP
  • nanoparticles such as Gold NP (nano particle), Liposome NP, Magnetic NP, and Polymeric NP can enter the cytoplasm through the cell membrane by endocytosis.
  • most of the complexes of nanoparticles and target proteins are degraded in lysosomes in cells. If the target protein is degraded inside the lysosome, the activity of the protein is lost. Furthermore, it is difficult to separate the target protein and the nanoparticles in the cytoplasm, and the toxicity of the nanoparticles may
  • Exosome is a small vesicle with a membrane structure in the size of 50 ⁇ 200 nm, which is secreted out of the cell with containing protein, DNA, and RNA for intercellular signaling.
  • Exosome was first found in the process of leaving only hemoglobin in the red blood cells by eliminating intracellular proteins at the last stage of red cell maturation. From the observation under electron microscope, it was confirmed that exosome is not separated directly from plasma membrane but discharged extracellular from the intracellular specific zone, called multivesicular bodies (MVBs). That is, when MVBs are fused with plasma membrane, such vesicles are discharged outside of the cell, which are called exosome.
  • MVBs multivesicular bodies
  • Exosome contains various intracellular proteins, DNA, and RNA. These substances contained in the exosome secreted out of the cell and can be reintroduced into other cells by fusion or endocytosis and serve as intercellular messengers.
  • Exosomes with the desired protein inside can be used to treat various diseases in vivo. This requires efficient production of exosomes containing target proteins.
  • Korean Patent Registration No. 10-0519384 discloses a method comprising:
  • the exosome is formed naturally in cells, even when a gene encoding a target protein is introduced into the production cells, the possibility of preparing the exosome containing the target protein is very low. There is a problem that the delivery efficiency of the exosome to the target tissue is low.
  • the tetraspanin family has four transmembrane domains, intracellular N- and C-termini and two extracellular loops protrude between the first and second, and third and fourth transmembrane domains.
  • CD9 is a 24-27 kD sized cell surface glycoprotein receptor belonging to the tetraspanin family, which regulates signal transduction actions important for regulating cell development, activity, growth and motility. In addition, it can regulate cell adhesion and cell migration and induces platelet activation involved in platelet-induced endothelial cell proliferation. In addition, it promotes muscle cell fusion and contributes to the maintenance of root canal.
  • the present invention provides a method for producing an exosome for target specific delivery comprising: preparing an expression vector by inserting a target peptide into an extracellular membrane domain of a transmembrane protein of an exosome; and producing the exosome comprising the target peptide located at the exosome membrane. Further, the present invention shows that the inserted target peptide is well expressed in HEK293T cells and that an active substance trapped in the exosome is well transferred into a target tissue.
  • a certain embodiment of the present invention provides a method for producing the exosome that transfers the active substance specifically to the target tissue and the exosome produced by the same.
  • Another embodiment of the present invention provides a method for delivering the active substance to the target tissue using the exosome. Still another embodiment of the present invention provides a pharmaceutical composition for the delivery of an active substance comprising the exosome as an active ingredient.
  • Still another embodiment of the present invention provides an expression vector wherein the target peptide is inserted into the extracellular membrane domain of the transmembrane protein.
  • Figure 1A is a schematic diagram of a pSF-CMV-CMV-Sbfl vector comprising a CIBN gene, an EGFP gene, and a target peptide inserted CD9 gene complex
  • Figure IB is a brief diagram showing insertion location of the target peptide in the CD9 protein structure.
  • Figure 2 is an image showing the expression of an Angiopeptin-2 peptide complex in HEK293T cells treated with the exosome comprising the Angiopeptin-2 peptide complex.
  • Figure 3 is an image showing the expression of an ApoB peptide complex in HEK293T cells treated with the exosome comprising the ApoB peptide complex.
  • Figure 4 is an image showing the expression of an ApoE peptide complex in HEK293T cells treated with the exosome comprising the ApoE peptide complex.
  • Figure 5 is an image showing the expression of a VCAM-1 internalization sequence peptide complex in HEK293T cells treated with the exosome comprising the VCAM-1 internalization sequence peptide complex.
  • Figure 6 shows a schematic diagram of a pSF-CMV-CMV-Sbfl vector comprising a Cre recombinase-CRY2 gene, the CIBN gene, the EGFP gene, and the target peptide inserted CD9 gene complex.
  • the present invention provides the method for producing the exosome that delivers the active substance specifically to the target tissue and the exosome produced by the same.
  • Still another embodiment of the present invention provides the expression vector wherein the target peptide is inserted into the extracellular membrane domain of the transmembrane protein.
  • the present invention relates to 1) the method for preparing the expression vector by inserting the target peptide into the extracellular membrane domain of the transmembrane protein of the exosome; and 2) the method for producing the exosome for target specific delivery of the active substance by introducing the said expression vector into an exosome- producing cell.
  • transmembrane protein is a protein which locates and attached to the lipid bilayer of cells. It has hydrophobic regions containing a high fraction of polar amino acids. Certain hydrophobic regions locate inside the bilayer while more hydrophilic regions are in contact with the aqueous intracellular and extracellular environments.
  • the transmembrane protein is selected from the group such as, but not limited to tetraspanin, integrin, ICAM-1, MHC-I, MHC-II, annexin and Rab.
  • tetraspanin is a membrane protein that has four
  • the tetraspanin is one or more proteins selected from the group comprising CD9, CD37, CD53, CD63, CD81 and CD82. In one embodiment of the invention, the tetraspanin is CD9.
  • target peptide is a peptide capable of transferring a substance to a specific site in vivo. It is expressed on the surface of the exosome, allowing the exosome to migrate to the specific tissue. According to the present invention, any peptide able to migrate to the specific tissue can be used as the target peptide.
  • the target peptide is selected from but not limited to angiopeptin-2, ApoB, ApoE, VCAM-1 internalization sequence, striated muscle target peptide, Peptide-22, THR, THR retro- enantio, CTR, Leptin 20, RVG 29, CDX, Apamin, MiniAp-4, GSH, G23, g7, TGN, TAT(45-57), SynBl, Diketopeperazines and PhPro.
  • the target peptide is inserted into the extracellular membrane domain of the transmembrane protein, wherein the insertion does not affect the expression or the function of the transmembrane.
  • the target peptide is inserted between amino acid position 170 -171 from the N-terminus of the CD9 (SEQ ID NO: 3).
  • the term "specific site” as used herein, is the specific tissue where the target peptide migrates to.
  • the specific site is selected from but not limited to blood brain barrier, inflamed blood vessels, striated muscle, liver and cancer tissue.
  • the "expression vector” refers to a recombinant vector capable of expressing a desired peptide from a desired host cell, including an operatively linked necessary regulatory element to express the gene insert.
  • the expression vector comprises expression control elements such as an initiation codon, a termination codon, a promoter, and an operator, etc.
  • the initiation codon and the termination codon are generally considered as a nucleotide sequence and must be in frame with a coding sequence to encode a polypeptide.
  • the promoter of the vector can be constitutive or inducible.
  • operably linked means a functional linkage between a nucleic acid expression sequence and a nucleic acid sequence encoding a desired protein or RNA to perform a general function.
  • the expression of the coding sequence can be affected by operably linked a promoter and the protein or RNA coding nucleic sequence.
  • the operable linkage with the expression vector can be produced by using recombinant DNA techniques well known in the art. A site-specific DNA cleavage and linkage can be achieved by using enzymes generally known in the art.
  • the expression vector may further includes a "selection marker". Selection markers are markers for selection of a transformed microorganism or a recombinant vector which is used to confer selectable phenotypes, such as drug resistance, nutritional
  • the transformed cells are selected using the vector containing the selection marker, as only the cells expressing the selection marker in the selected agent's environment can survive.
  • the selection marker is selected from but not limited to the antibiotic resistance gene, for example kanamycin, ampicillin, and puromycin.
  • the "exosome-producing cell” is one or more selected from the group consisting of B- lymphocytes, T-lymphocytes, dendritic cells, macrophage cells, macrophages, stem cells, and tumor cells.
  • the exosome-producing cell is HEK293T cell.
  • the term "active substance” refers to a substance that enhances or inhibits a biological function, wherein the active substance controls the secretion of substances that regulate the function of the human body exhibiting abnormal conditions.
  • the active substance is selected from but not limited to a protein drug, an enzyme, a nucleic acid, a chemical and a mixture thereof.
  • One embodiment of the present invention provides the pSF-CMV-CMV-Sbfl vector comprising the CIBN gene, the EGFP gene, and the target peptide complex inserted CD9 encoding gene, wherein the target peptide is selected from but not limited to angiopeptin-2, ApoB, ApoE, VCAM-1 internalization sequence, striated muscle target peptide, Peptide-22, THR, THR retro-enantio, CTR, Leptin 20, RVG 29, CDX, Apamin, MiniAp-4, GSH, G23, g7, TGN, TAT(45- 57), SynBl, Diketopeperazines and PhPro.
  • the target peptide is selected from but not limited to angiopeptin-2, ApoB, ApoE, VCAM-1 internalization sequence, striated muscle target peptide, Peptide-22, THR, THR retro-enantio, CTR, Leptin 20, RVG 29, CDX, Apamin, MiniAp-4
  • the said vector is introduced into exosome- producing cells such as HEK293T cells to obtain exosomes with target peptide labeled in the membrane protein ( Figure 1).
  • Figures 2 and 5 show the expression of the target peptide in exosome membrane protein.
  • the present invention also provides the method for producing the exosome for target specific delivery of the active substance comprising:
  • step 2) introducing the expression vector of step 1) into the exosome-producing cell.
  • the transmembrane protein is selected from the group such as, but not limited to tetraspanin, integrin, ICAM-1, MHC-I, MHC-II, annexin and Rab.
  • the tetraspanin is selected from the group consisting CD9, CD37, CD53, CD63, CD81 and CD82. In one embodiment of the invention, the tetraspanin is CD9.
  • the target peptide is any peptides able to migrate to the specific tissue.
  • the target peptide is selected from but not limited to
  • the exosome-producing cell is one or more selected from the group comprising B- lymphocytes, T-lymphocytes, dendritic cells, macrophage cells, macrophages, stem cells, or tumor cells.
  • the exosome-producing cell is HEK293T cell.
  • the present invention provides the pSF-CMV-CMV-Sbfl vector comprising the CIBN gene, the EGFP gene, and the target peptide complex inserted CD9 encoding gene, wherein the target peptide is selected from but not limited to angiopeptin-2, ApoB, ApoE, VCAM-1 internalization sequence and striated muscle target peptide.
  • the said vector is introduced into exosome-producing cells such as HEK293T cells to obtain exosomes with target peptide labeled in the membrane protein (Figure IB).
  • Figures 2 and 5 shows the expression of the target peptide in exosome membrane protein.
  • the present invention also provides the method for delivering the active substance to the target tissue using the exosome prepared by the method of the present invention.
  • the method comprises:
  • step 2) introducing the expression vector of step 1) into the exosome-producing cell.
  • the transmembrane protein is selected from the group such as, but not limited to tetraspanin, integrin, ICAM-1, MHC-I, MHC-II, annexin and Rab.
  • the tetraspanin is selected from the group consisting CD9, CD37, CD53, CD63, CD81 and CD82.
  • the tetraspanin is CD9.
  • the target peptide is any peptides able to migrate to the specific tissue.
  • the target peptide is selected from but not limited to
  • the exosome-producing cell is one or more selected from the group comprising B- lymphocytes, T-lymphocytes, dendritic cells, macrophage cells, macrophages, stem cells, or tumor cells.
  • the exosome-producing cell is HEK293T cell.
  • the present invention provides the pSF-CMV-CMV-Sbfl vector comprising the CIBN gene, the EGFP gene, and the target peptide complex inserted CD9 encoding gene, wherein the target peptide is selected from but not limited to angiopeptin-2, ApoB, ApoE, VCAM-1 internalization sequence and striated muscle target peptide.
  • the said vector is introduced into exosome-producing cells such as HEK293T cells to obtain exosomes with target peptide labeled in the membrane protein (Figure IB).
  • Figures 2 and 5 shows the expression of the target peptide in exosome membrane protein.
  • the present invention also provides the pharmaceutical composition for the delivery of the active substance comprising the exosome as the active ingredient, wherein the amount of the exosome is about 10 to about 95% of the total weight of the composition.
  • the pharmaceutical composition of the present invention further comprises one or more active ingredients showing the same or similar functions to the above-mentioned active ingredient.
  • composition of the present invention further comprises
  • the pharmaceutically acceptable carrier is selected from but not limited to, chemicals listed in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and a mixture thereof.
  • the pharmaceutical composition further comprises other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent.
  • the pharmaceutical composition further comprises a diluent or an excipient such as a filler, an extender, a binder, a wetting agent, a disintegrating agent, and a surfactant.
  • the pharmaceutical composition of the present invention is formulated into an oral or a parenteral preparation.
  • a solid formulation for the oral administration includes tablets, pills, powders, granules, capsules, troches and thereof.
  • the solid formulation for the oral administration comprises one or more excipients such as starch, calcium carbonate, sucrose, lactose, gelatin, and thereof.
  • the solid formulation further comprises lubricants such as magnesium stearate and talc.
  • a liquid formulation for the oral administration includes suspensions, solutions, emulsions, syrups and thereof.
  • the liquid formulation comprises wetting agents, sweeteners, fragrances, preservatives and thereof.
  • the parenteral administration includes injections such as sterile aqueous solutions, nonaqueous solutions, suspensions, and emulsions.
  • the non-aqueous solvent and the suspending agent is selected from the group comprising propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, or thereof.
  • the pharmaceutical composition of the present invention is administered orally or parenterally according to the desired method.
  • the parenteral administration is selected from external and intraperitoneal injection, intraperitoneal injection is selected from but not limited to rectal injection, subcutaneous injection, intravenous injection, and intramuscular injection.
  • the pharmaceutical composition according to the invention is administered in a pharmaceutically effective amount.
  • the pharmaceutical effective amount varies on the type of disease, severity, activity of the drug, sensitivity to the drug, administration time,
  • administration route rate of excretion, duration of treatment, concurrent medication and thereof.
  • the pharmaceutical composition of the present invention is administered alone or in combination with other therapeutic agents.
  • administration may be sequential or simultaneous.
  • the pharmaceutical composition of the present invention comprises the active ingredient wherein the pharmaceutically effective amount is 0.001 - lOg/Kg, 0.01 - 8g/Kg or 0.1 - 5 g/Kg.
  • the administration can be once or several times a day.
  • the present invention provides the expression vector wherein the target peptide is inserted into the extracellular domain of the transmembrane protein.
  • the transmembrane protein is selected from the group such as, but not limited to tetraspanin, integrin, ICAM-1, MHC-I, MHC-II, annexin and Rab.
  • the tetraspanin is one or more proteins selected from the group comprising CD9, CD37, CD53, CD63, CD81 or CD82. In one embodiment of the invention, the tetraspanin is CD9.
  • the target peptide is selected from but not limited to angiopeptin-2, ApoB, ApoE, VCAM-1 internalization sequence, striated muscle target peptide, Peptide-22, THR, THR retro- enantio, CTR, Leptin 20, RVG 29, CDX, Apamin, MiniAp-4, GSH, G23, g7, TGN, TAT(45-57), SynBl, Diketopeperazines and PhPro.
  • the expression vector is the recombinant vector capable of expressing the peptide of interest from the desired host cell, including the operatively linked necessary regulatory element to express the gene insert.
  • the expression cells further comprise the selection marker.
  • the selection marker is selected from but not limited to the antibiotic resistance gene, such as kanamycin, ampicillin, or puromycin. Any selection marker known in the art can be used.
  • the pharmaceutical composition may further comprises one or more other component compositions, solutions or devices suitable for the introduction of the expression vector, the culturing the transformed exosome producing cell, or the isolation and purification of the exosome produced from the transformed cells.
  • the composition further comprises a buffer suitable for the introduction of the expression vector, a medium and a container necessary for the culturing the transformed exosome producing cell and thereof.
  • An embodiment of the present invention provides the pSF-CMV-CMV-Sbfl vector comprising the CIBN gene, the EGFP gene, and the target peptide complex inserted CD9 encoding gene, wherein the target peptide is selected from but not limited to angiopeptin-2, ApoB, ApoE, VCAM-1 internalization sequence and striated muscle target peptide.
  • the said vector is introduced into exosome-producing cells such as HEK293T cells to obtain exosomes with target peptide labeled in the membrane protein ( Figure 1). Figures 2 and 5 shows the expression of the target peptide in exosome membrane protein.
  • Angiopeptin-2 is a protein targeting the blood-brain barrier.
  • An exosome labeled with the Angiopeptin-2 peptide in the exosome membrane protein was prepared by the following method.
  • a multicloning site of pSF-CMV-CMV-Sbfl vector (# OG411, Oxford Genetics, UK), Ndel, was digested with Ndel restriction enzyme to linearize the DNA.
  • the CIBN gene (SEQ ID NO: 1)
  • the EGFP gene (SEQ ID NO: 2)
  • a gene fragment of CD9 encoding 1-170 amino acids from the N-terminal a gene fragment of CD9 encoding 171-228 amino acids from the N-terminal
  • a gene fragment encoding the angiopeptin-2 peptide complex (SEQ ID NO: 4) was prepared by PCR.
  • the Ndel portion of the pSF-CMV-CMV-Sbfl vector was sequentially connected by Gibson assembly so that the two ends of the three fragments were overlapped with each other by 20 to 24 bp in order to obtain vector having a sequence of CIBN- EGFP-CD9 (l-170)-angiopeptin-2 peptide complex-CD9(171-228).
  • the angiopeptin-2 peptide complex is consisting with three repeated angiopeptin-2 amino acid sequences (SEQ ID NO: 5), and a linker described by the amino acid sequence of GGGGS (SEQ ID NO: 6) is located between angiopeptin-2 amino acid sequences, and a linker described in the amino acid sequence of PPVAT (SEQ ID NO: 7) is inserted at both ends of the angiopeptin-2 sequences.
  • the vector encoding CIBN-EGFP-CD9 (l-170)-angiopeptin 2 complex-CD9 (171-228) was introduced into HEK293T cells as exosome-producing cells. 24 hours incubation was followed by 48 hours incubation in the media without fetal bovine serum. The culture was centrifuged at 1,000 rpm for 3 minutes and was filtered using a polyethersulfone membrane having a pore size of 0.2 ⁇ . The filtrate was first concentrated through tangential flow filtration at 4 °C. The concentrate was then purified using size exclusion chromatography with a sepharose bead at 4 ° C.
  • the ApoB is a protein targeting the blood-brain barrier, and the exosome labeled with the ApoB peptide complex in the exosomal membrane was prepared by the following method.
  • the same steps described in Example 1 were carried out, except only the ApoB peptide complex (SEQ ID NO: 8) was inserted to obtain the exosome labeled with the ApoB peptide complex in the exosomal membrane.
  • the ApoB peptide complex is consisting with three repeated ApoB amino acid sequences (SEQ ID NO: 9), and the linker described by the amino acid sequence of GGGGS (SEQ ID NO: 6) is located between ApoB amino acid sequences, and the linker described in the amino acid sequence of PPVAT (SEQ ID NO: 7) is inserted at both ends of the ApoB sequences.
  • the ApoE is a protein targeting the blood-brain barrier, and the exosome labeled with the ApoE peptide complex in exosomal membrane was prepared by the following method.
  • Example 4 Production of exosomes labeled with VCAM-1 internalization sequence peptide complex in exosomal membrane
  • VCAM-1 vascular cell adhesion molecule-1
  • VCAM-1 internalization sequence peptide complex in the exosomal membrane was prepared by the following method.
  • VCAM-1 internalization sequence peptide complex (SEQ ID NO: 12) was inserted to obtain the exosome labeled with the VCAM-1 internalization sequence peptide complex in the exosomal membrane.
  • the VCAM-1 internalization sequence peptide complex is consisting with three repeated VCAM-1 internalization amino acid sequences (SEQ ID NO: 13), and the linker described by the amino acid sequence of GGGGS (SEQ ID NO: 6) is located between VCAM-1 internalization sequences, and the linker described in the amino acid sequence of PPVAT (SEQ ID NO: 7) is inserted at both ends of the VCAM-1 internalization sequences.
  • the striated muscle target peptide is a protein targeting striated muscle, and the exosome labeled with the straited muscle target peptide in the exosomal membrane was prepared by the following method.
  • Striated muscle target peptide complexes are consisting with three repeated amino acid sequence, ASSLNIA (SEQ ID NO: 17), TARGEHKEEELI (SEQ ID NO: 18) or SKTFNTHPQSTP (SEQ ID NO: 19), the linker described by the amino acid sequence of GGGGS (SEQ ID NO: 6) is located between sequences, and the linker described in the amino acid sequence of PPVAT (SEQ ID NO: 7) is inserted at both ends of the sequences.
  • Example 6 Expression of angiopopein-2 Peptide Complex
  • the exosome of Example 1 was transfected to HEK293T cells.
  • the expression of the angioprotein-2 peptide complex in the exosomal membrane was confirmed through a fluorescence microscope after 24 hours.
  • Figure 2 shows the expression of the angioprotein -2 peptide complex in the exosomal membrane.
  • Example 2 The exosome of Example 2 was transfected to HEK293T cells.
  • the expression of the ApoB peptide complex in the exosomal membrane was confirmed through the fluorescence microscope after 24 hours.
  • Figure 3 shows the expression of the ApoB peptide complex in the exosomal membrane.
  • Example 3 The exosome of Example 3 was transfected to HEK293T cells.
  • the expression of the ApoE peptide complex in the exosomal membrane was confirmed through the fluorescence microscope after 24 hours.
  • Figure 4 shows the expression of the ApoE peptide complex in the exosomal membrane.
  • Example 4 The exosome of Example 4 was transfected to HEK293T cells.
  • the expression of the VCAM-1 internalization sequence peptide complex in the exosomal membrane was confirmed through the fluorescence microscope after 24 hours.
  • Figure 5 shows the expression of the VCAM-1 internalization sequence peptide complex in the exosomal membrane.
  • Example 5 The exosome of Example 5 was transfected to HEK293T cells. The expression of the striated muscle target peptide complex in the exosomal membrane was confirmed through the fluorescence microscope after 24 hours. The expression of the striated muscle target peptide complex in the exosomal membrane was confirmed.
  • Example 11 Target-specific delivery of exosomes labeled with angiopeptin-2 peptide complex on exosomal membrane
  • the vector encoding CIBN-EGFP-CD9(l-170)-angiopeptin 2 peptide complex-CD9(171- 228) was obtained with the same steps described in Example 1, except that an additional Cre recombinase-CRY2 gene was further inserted under an LED emitting light of 460 nm at an intensity of 100 ⁇ .
  • the vector was introduced to H EK293T as the exosome production cell. 24 hours incubation was followed by 48 hours incubation in the media without fetal bovine serum under the LED light.
  • the culture medium was separated by tangential flow filtration and size exclusion chromatography to obtain exosomes labeled with the angiopeptin-2 peptide complex in the exosomal membrane.
  • An exosome in which angiopeptin-2 peptide complex was not labeled on the exosomal membrane was used as a control group.
  • the resulting exosome at a concentration of 1 x 10 9 particles/50 ⁇ was injected intravenously or intraperitoneally into the blood vessels of C57BL/6 loxP-eNphr3.0-loxP-eYFP TG mice (The Jackson Laboratory, Bar Harbor, Maine, USA) and organs were excised and histo-pathologically examined 48 or 72 hours after the injection.
  • the distribution of eYFP in mice was analyzed to determine the function and distribution of the exosome labeled with the specific target peptide in vivo.
  • the vector encoding CIBN-EGFP-CD9(l-170)-ApoB peptide complex-CD9(171-228) was obtained the same steps described in Example 2, except that the additional Cre recombinase- CRY2 gene was further inserted under the LED emitting light of 460 nm at the intensity of 100 ⁇ . Same steps described in Example 11 were carried out to determine the function and the distribution of the exosome labeled with the specific target peptide in vivo.
  • the vector encoding CIBN-EGFP-CD9(l-170)-ApoE peptide complex-CD9(171-228) was obtained the same steps described in Example 3, except that the additional Cre recombinase- CRY2 gene was further inserted under the LED emitting light of 460 nm at the intensity of 100 ⁇ . Same steps described in Example 11 were carried out to determine the function and the distribution of the exosome labeled with the specific target peptide in vivo.
  • the exosome labeled with the ApoE peptide complex was specifically transferred to the blood brain barrier.
  • Example 14 Target-specific delivery effect of exosome labeled with VCAM-1 internalization sequence peptide complex in exosomal membrane
  • the vector encoding CIBN-EGFP-CD9(1-170)-VCAM-1 internalization sequence peptide complex-CD9(171-228) was obtained the same steps described in Example 4, except that the additional Cre recombinase-CRY2 gene was further inserted under the LED emitting light of 460 nm at the intensity of 100 ⁇ . Same steps described in Example 11 were carried out to determine the function and the distribution of the exosome labeled with the specific target peptide in vivo.
  • Example 15 Target-specific delivery effect of exosome labeled with striated muscle target peptide complex in exosomal membrane
  • the vector encoding CIBN-EGFP-CD9(l-170)-striated muscle target peptide complex- CD9(171-228) was obtained the same steps described in Example 5, except that the additional Cre recombinase-CRY2 gene was further inserted under the LED emitting light of 460 nm at the intensity of 100 ⁇ . Same steps described in Example 11 were carried out to determine the function and the distribution of the exosome labeled with the specific target peptide in vivo. As a result, it was confirmed that exosome labeled with the striated muscle target peptide complex in the membrane protein was specifically transferred to the striated muscle.
  • striated muscle target peptide complex ⁇ 400> 15 Pro Pro Val Ala Thr Thr Ala Arg Gly Glu His Lys Glu Glu Glu Leu 1 5 10 15
  • striated muscle target peptide complex ⁇ 400> 16 Pro Pro Val Ala Thr Ser Lys Thr Phe Asn Thr His Pro Gin Ser Thr 1 5 10 15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé de production d'un exosome qui transfère une substance active spécifiquement à une cible, et l'exosome produit par ledit procédé; un procédé d'administration de la substance active au tissu cible à l'aide de l'exosome; une composition pharmaceutique pour l'administration de la substance active comprenant l'exosome en tant que principe actif; et une composition pour préparer l'exosome comprenant un vecteur d'expression où le peptide cible est inséré dans une partie extracellulaire d'une protéine transmembranaire.
PCT/IB2018/056200 2017-08-17 2018-08-16 Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci WO2019035057A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201880067512.6A CN111629761B (zh) 2017-08-17 2018-08-16 用于靶特异性递送的外泌体以及用于制备和递送该外泌体的方法
JP2020530742A JP7224352B2 (ja) 2017-08-17 2018-08-16 標的特異的伝達のためのエクソソーム及びこれを製造及び伝達する方法
CA3073162A CA3073162C (fr) 2017-08-17 2018-08-16 Exosomes pour administration specifique a une cible et procedes de preparation et d'administration de ceux-ci
AU2018316803A AU2018316803B2 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
US16/639,740 US20200206360A1 (en) 2017-08-17 2018-08-16 Exosomes for target specific delivery and methods for preparing and delivering the same
EP18846900.1A EP3668552A4 (fr) 2017-08-17 2018-08-16 Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci
IL272684A IL272684A (en) 2017-08-17 2020-02-16 Exosomes for specific delivery of a target and methods for its preparation and delivery
AU2021250906A AU2021250906B2 (en) 2017-08-17 2021-10-13 Exosomes for target specific delivery and methods for preparing and delivering the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0104171 2017-08-17
KR20170104171 2017-08-17
US201862659816P 2018-04-19 2018-04-19
US62/659,816 2018-04-19

Publications (2)

Publication Number Publication Date
WO2019035057A2 true WO2019035057A2 (fr) 2019-02-21
WO2019035057A3 WO2019035057A3 (fr) 2019-04-25

Family

ID=65361814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/056200 WO2019035057A2 (fr) 2017-08-17 2018-08-16 Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci

Country Status (2)

Country Link
KR (1) KR102100420B1 (fr)
WO (1) WO2019035057A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021172596A1 (fr) * 2020-02-28 2021-09-02 国立大学法人金沢大学 Procédé d'immunosuppression, et composition d'acide nucléique pour immunosuppression ainsi qu'application de celle-ci
WO2021184017A1 (fr) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Vésicules extracellulaires pour le traitement de troubles neurologiques
WO2021233346A1 (fr) * 2020-05-19 2021-11-25 首都医科大学附属北京天坛医院 Exosome modifié de manière ciblée chargé de médicament et son procédé de préparation et son utilisation
CN114173807A (zh) * 2019-09-02 2022-03-11 庆北大学校产学协力团 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物
JP2022539228A (ja) * 2019-07-02 2022-09-07 インダストリー－ユニバーシティー コーペレイション ファンデーション ハンヤン ユニバーシティー エリカ キャンパス 植物エクソソームの大量生産方法
EP4009989A4 (fr) * 2019-08-06 2023-08-23 Ohio State Innovation Foundation Vésicules extracellulaires thérapeutiques

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102341138B1 (ko) * 2020-05-31 2021-12-21 주식회사 엑소코바이오 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법
KR20220148567A (ko) * 2021-04-29 2022-11-07 주식회사 서지넥스 약물전달물질로서의 간세포암 특이적 표적 엑소좀 조성물 및 이의 용도
KR20220148568A (ko) * 2021-04-29 2022-11-07 주식회사 서지넥스 약물전달물질로서의 대장암 특이적 표적 엑소좀 조성물 및 이의 용도
KR102620197B1 (ko) * 2021-04-30 2024-01-02 가톨릭대학교 산학협력단 약물전달물질로서의 대장암 특이적 표적 엑소좀 조성물 및 이의 용도
KR102632530B1 (ko) * 2021-05-24 2024-02-02 가톨릭대학교 산학협력단 약물전달물질로서의 위암 특이적 표적 엑소좀 조성물 및 이의 용도
KR20230013009A (ko) 2021-07-16 2023-01-26 서울대학교산학협력단 세포외 소포체 및 그 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3335721A1 (fr) * 2013-04-12 2018-06-20 Evox Therapeutics Limited Vésicules d'administration thérapeutique
WO2015002956A1 (fr) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Système de distribution d'exosome
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022539228A (ja) * 2019-07-02 2022-09-07 インダストリー－ユニバーシティー コーペレイション ファンデーション ハンヤン ユニバーシティー エリカ キャンパス 植物エクソソームの大量生産方法
EP4009989A4 (fr) * 2019-08-06 2023-08-23 Ohio State Innovation Foundation Vésicules extracellulaires thérapeutiques
CN114173807A (zh) * 2019-09-02 2022-03-11 庆北大学校产学协力团 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物
CN114173807B (zh) * 2019-09-02 2024-03-19 庆北大学校产学协力团 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物
WO2021172596A1 (fr) * 2020-02-28 2021-09-02 国立大学法人金沢大学 Procédé d'immunosuppression, et composition d'acide nucléique pour immunosuppression ainsi qu'application de celle-ci
WO2021172595A1 (fr) * 2020-02-28 2021-09-02 国立大学法人金沢大学 Vésicule extracellulaire de présentation d'antigène, composition contenant celle-ci, et procédé destiné à la fabrication de celles-ci
WO2021184017A1 (fr) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Vésicules extracellulaires pour le traitement de troubles neurologiques
WO2021233346A1 (fr) * 2020-05-19 2021-11-25 首都医科大学附属北京天坛医院 Exosome modifié de manière ciblée chargé de médicament et son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
KR102100420B9 (ko) 2022-01-19
KR102100420B1 (ko) 2020-04-13
WO2019035057A3 (fr) 2019-04-25
KR20190019872A (ko) 2019-02-27

Similar Documents

Publication Publication Date Title
WO2019035057A2 (fr) Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci
AU2018316803B2 (en) Exosomes for target specific delivery and methods for preparing and delivering the same
JP6392427B2 (ja) ｐ９７−抗体結合体および使用方法
US10131888B2 (en) Intracellular protein delivery
JP3581366B2 (ja) 免疫原のリソソーム標的
KR101841211B1 (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
JP2024029097A (ja) ミニヌクレオソームコアタンパク質及び核酸送達における使用
KR101778244B1 (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
US20200299654A1 (en) Cdkl5 expression variants and cdkl5 fusion proteins
JP2012507278A (ja) 短縮型ヒトｒｎａｓｅｔ２の大腸菌における効率的発現
WO2019212031A1 (fr) Peptide et son utilisation
EP4136235A1 (fr) Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846900

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3073162

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020530742

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018846900

Country of ref document: EP

Effective date: 20200317

ENP Entry into the national phase

Ref document number: 2018316803

Country of ref document: AU

Date of ref document: 20180816

Kind code of ref document: A